889864-59-9

Upstream product

• 136412-37-8 ((S)-2-Oxo-1-phenyl-2-piperidin-1-yl-ethyl)-carbamic acid benzyl ester 
• 796046-10-1 C₁₈H₂₆N₂O₃ 
• 5491-18-9 (S)-N-(benzyloxycarbonyl)phenylglycine 

Downstream Products

• 889864-36-2 C₃₆H₃₃F₃N₄O₄ 
• 889864-45-3 C₃₃H₃₄F₃N₃O₃ 
• 889864-01-1 C₃₅H₃₂F₃N₃O₄ 
• 889864-20-4 C₃₅H₃₂F₃N₃O₃ 
• 889864-10-2 C₃₅H₃₂F₃N₃O₄ 
• 148076-28-2 Methyl-[((S)-2-oxo-1-phenyl-2-piperidin-1-yl-ethylcarbamoyl)-methyl]-carbamic acid benzyl ester 
• 148054-65-3 (S)-(+)-1-(2-amino-2-phenylethyl)piperidine 

Relevant academic research and scientific papers

Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents

We have successfully identified a number of novel MTP inhibitors with single digit nanomolar potency. Analogues 10aq and 10dq demonstrated in vivo efficacy in a murine gut retention assay.

Enantioselective conjugate addition to cyclic enones with scalemic lithium organo(amido)cuprates, part IV. Relationship between ligand structure and enantioselectivity

Scalemic lithium amides derived from primary and secondary amines react with organocopper compounds in ether or dimethyl sulfide to form lithium organo(amido)cuprates capable of enantioselective conjugate addition to 2-cycloalkenones. The most successful heterocuprate, in which the chiral ligand is (S)-N-methyl-1-phenyl-2-(1-piperidinyl)ethanamine, (S)-MAPP, 13, reacts with cyclic enones to form products with up to 97% ee. Nonlinear asymmetric induction was observed with the cuprate formed from ligand 13.